.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,410,172

« Back to Dashboard

Details for Patent: 8,410,172

Title:Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
Abstract: The present invention relates to compounds being esters of 5-aminolevulinic acids or pharmaceutically acceptable salts thereof, including compounds of formula (I) R.sup.2.sub.2N--CH.sub.2COCH.sub.2--CH.sub.2CO--OR.sup.1 (wherein R.sup.1 may represent alkyl optionally substituted by hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, oxo or fluoro groups and optionally interrupted by oxygen, nitrogen, sulphur or phosphorus atoms; and R.sub.2 represents a hydrogen atom or a group R.sub.1, and both R.sub.2 groups may be the identical or different), and their use in diagnosis and photochemotherapy of disorders or abnormalities of external or internal surfaces of the body, and products and kits for performing the invention.
Inventor(s): Gierskcky; Karl E. (Hosle, NO), Moan; Johan (Oslo, NO), Peng; Qian (Oslo, NO), Steen; Harald (Oslo, NO), Warloe; Trond (Oslo, NO), Bjorseth; Alf (Oslo, NO)
Assignee: Photocure ASA (Oslo, NO)
Filing Date:Dec 06, 2010
Application Number:12/961,420
Claims:1. A pharmaceutical composition comprising (a) a compound of formula (I) R.sup.2.sub.2N--CH.sub.2COCH.sub.2--CH.sub.2CO--OR.sup.1 (I) wherein, R.sup.1 is alkyl; and each R.sup.2 is independently hydrogen or alkyl; wherein each alkyl of R.sup.1 and R.sup.2 is optionally substituted by hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, oxo or fluoro groups and is optionally interrupted by oxygen atoms; or a pharmaceutically acceptable salt thereof, wherein the composition is in the form of an ointment or pessary.

2. The composition of claim 1, wherein the composition is in the form of an ointment.

3. The composition of claim 2, wherein the composition further comprises an oily base.

4. The composition of claim 3, wherein the composition further comprises a thickening agent.

5. The composition of claim 1, wherein the composition is in the form of a pessary.

6. The composition of claim 1, wherein, in the compound of formula (I), R.sup.1 represents an unsubstituted alkyl group and each R.sup.2 is hydrogen.

7. The composition of claim 6, wherein the compound of formula (I) is ALA-hexyl ester.

8. The composition of claim 7, wherein the composition comprises the hydrochloride salt of ALA-hexyl ester.

9. The composition of claim 1, wherein the concentration of the compound of formula (I) or the pharmaceutically acceptable salt thereof is 1-50% (w/w).

10. The composition of claim 9, wherein the concentration of the compound of formula (I) or the pharmaceutically acceptable salt thereof is 1-5% (w/w).

11. A method for the treatment of abnormalities or disorders of an internal or external surface of the body, comprising: (i) administering to the affected surface a composition comprising (a) a compound of formula (I) R.sup.2.sub.2N--CH.sub.2COCH.sub.2--CH.sub.2CO--OR.sup.1 (I) wherein, R.sup.1 is alkyl; and each R.sup.2 is independently hydrogen or alkyl; wherein each alkyl of R.sup.1 and R.sup.2 is optionally substituted by hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, oxo or fluoro groups and is optionally interrupted by oxygen atoms; or a pharmaceutically acceptable salt thereof; and (ii) exposing said surface to light, wherein the internal or external surface of the body is the lining of the female genital tract.

12. The method of claim 11, wherein the composition is in the form of an ointment.

13. The method of claim 11, wherein the composition is in the form of a pessary.

14. The method of claim 11, wherein, in the compound of formula (I), R.sup.1 represents an unsubstituted alkyl group and each R.sup.2 is hydrogen.

15. The method of claim 11 wherein the lining is that of the vagina.

16. The method of claim 11 wherein the lining is that of the uterine cervix.

17. The method of claim 11 wherein the lining is that of the uterus.

18. The method of claim 11, wherein the abnormality or disorder is an infection.

19. The method of claim 18, wherein the abnormality or disorder is a viral infection.

20. The method of claim 19, wherein the abnormality or disorder is a Herpes virus infection.

21. The method of claim 11, wherein the abnormality or disorder is a premalignant or malignant abnormality.

22. The method of claim 11, wherein the compound of formula (I) is ALA-hexyl ester.

23. The method of claim 22, wherein the compound in the composition is the hydrochloride salt of ALA-hexyl ester.

24. The method of claim 11, wherein the concentration of the compound in the composition is 1-50% (w/w).

25. The method of claim 11, wherein a period of 0.5-48 hours is permitted to elapse between administering the composition and exposing the sites or surfaces to light.

26. The method of claim 11, wherein the light has a wavelength of 350-640 nm.

27. The composition of claim 6, wherein the composition is in the form of a pessary.

28. The composition of claim 6, wherein the composition is in the form of an ointment.

29. The composition of claim 4 comprising the hydrochloride salt of ALA-hexyl ester in a concentration of 1-50% (w/w).

30. The method of claim 14, wherein the composition is in the form of an ointment.

31. The method of claim 14, wherein the composition is in the form of a pessary.

32. The method of claim 16, wherein the composition is in the form of an ointment that comprises the hydrochloride salt of ALA-hexyl ester in a concentration of 1-50% (w/w), an oily base and a thickening agent and further wherein the abnormality or disorder is a pre-malignant abnormality.

33. The method of claim 16, wherein the composition is in the form of an ointment that comprises the hydrochloride salt of ALA-hexyl ester in a concentration of 1-50% (w/w), an oily base and a thickening agent and further wherein the abnormality or disorder is a viral infection.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc